These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 24150190)

  • 21. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis.
    Huang S; Lin H; Zhu X; Chen X; Fan L; Liu C
    Endokrynol Pol; 2014; 65(2):96-104. PubMed ID: 24802732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New developments in the treatment of osteoporosis.
    Eriksen EF; Halse J; Moen MH
    Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for the prevention and treatment of osteoporosis during early postmenopause.
    Delaney MF
    Am J Obstet Gynecol; 2006 Feb; 194(2 Suppl):S12-23. PubMed ID: 16448872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteoporosis: handy tools for detection, helpful tips for treatment.
    Morgan SL; Kitchin B
    J Fam Pract; 2008 May; 57(5):311-20. PubMed ID: 18460296
    [No Abstract]   [Full Text] [Related]  

  • 25. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
    Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
    Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low rates of treatment in postmenopausal women with a history of low trauma fractures: results of audit in a Fracture Liaison Service.
    Premaor MO; Pilbrow L; Tonkin C; Adams M; Parker RA; Compston J
    QJM; 2010 Jan; 103(1):33-40. PubMed ID: 19864348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
    Eastell R; Rosen CJ; Black DM; Cheung AM; Murad MH; Shoback D
    J Clin Endocrinol Metab; 2019 May; 104(5):1595-1622. PubMed ID: 30907953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
    Miller RG
    Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fracture prevention in postmenopausal osteoporosis: a review of treatment options.
    McCarus DC
    Obstet Gynecol Surv; 2006 Jan; 61(1):39-50. PubMed ID: 16359568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ten-year fracture risk in the assessment of osteoporosis management efficacy in postmenopausal women: a pilot study.
    Pluskiewicz W; Drozdzowska B; Adamczyk P
    Climacteric; 2013 Feb; 16(1):117-26. PubMed ID: 22335356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
    Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Up-to-date treatments for osteoporosis].
    Bors K
    Orv Hetil; 2006 Feb; 147(7):301-6. PubMed ID: 17489157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
    Silverman SL; Shen W; Minshall ME; Xie S; Moses KH
    J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corticosteroids: no drug prevention of fractures needed.
    Prescrire Int; 2009 Aug; 18(102):175. PubMed ID: 19746563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of postmenopausal osteoporosis.
    Andreopoulou P; Bockman RS
    Annu Rev Med; 2015; 66():329-42. PubMed ID: 25386933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention and treatment of postmenopausal osteoporosis.
    Tella SH; Gallagher JC
    J Steroid Biochem Mol Biol; 2014 Jul; 142():155-70. PubMed ID: 24176761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The patient's page. Bone health facts.
    McKinney J
    South Med J; 2005 Oct; 98(10):1058. PubMed ID: 16295830
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.